Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Here, we demonstrate upregulation of multidrug transporters ABCB1 and ABCG2 as a major mode of resistance to THZ1, a covalent inhibitor of CDKs 7, 12, and 13 in neuroblastoma and lung cancer. 29276047 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Combination therapy showed a synergistic activity between doxorubicin and either bioconjugate or nanocarrier on BE(2)C. More interestingly, on BE(2)C/ADR we recorded both the reversion of doxorubicin resistance mechanism as a consequence of decreased P-gp expression (Western Blot analysis) and a synergistic effect on cell viability, confirming the proposed nanohybrid as a very promising starting point for further research in neuroblastoma treatment. 29129733 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed prolonged and elevated cytotoxicity of YM155.In addition, the drug combination (i.e. lapatinib plus YM155) decreased neuroblastoma tumor size in an in vivo model. 28596528 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. 28901962 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE In conclusion, we show that ABCB1 expression represents the primary (sometimes exclusive) resistance mechanism in neuroblastoma cells with acquired resistance to SNS-032. 27517323 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE Hypermethylation of the miR-137 promoter and negative regulation of miR-137 by CAR contribute in part to reduced miR-137 expression and increased CAR and MDR1 expression in doxorubicin-resistant neuroblastoma cells. 23934188 2014
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Study of the mechanisms underlying the reversal of multidrug resistance of human neuroblastoma multidrug-resistant cell line SK-N-SH/MDR1 by low-intensity pulsed ultrasound. 23483136 2013
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE We conclude that most neuroblastoma cell lines are sensitive to YM155 in the low nM range and that resistant cells can be sensitised by ABCB1 inhibitors. 22088485 2012
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Multidrug resistance protein 1 has been previously implicated in the development of drug resistance, particularly with regard to influencing clinical outcomes in neuroblastoma. 21317832 2011
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE To this end, we used an inducible siRNA (small interfering RNA) expression system to silence the expression of MRP1 and MDR1 in human neuroblastoma SH-SY5Y cells. 18713069 2009
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 PosttranslationalModification disease BEFREE Data from present study suggest that transcriptional inactivation of MDR1 gene due to increased MDR1 promoter methylation may be a contributing factor in pathogenesis and progression of neuroblastoma tumors, and may be used in designing an effective treatment therapy to neuroblastoma patients. 17387584 2007
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 PosttranslationalModification disease LHGDN Data from present study suggest that transcriptional inactivation of MDR1 gene due to increased MDR1 promoter methylation may be a contributing factor in pathogenesis and progression of neuroblastoma tumors, and may be used in designing an effective treatment therapy to neuroblastoma patients. 17387584 2007
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE The purpose of this study was to determine the activity of pyrazoloacridine (PZA) in neuroblastomas that have acquired high-level resistance to multiple drugs (not associated with multidrug resistance-associated protein or P-glycoprotein) during therapy, including those with loss of p53 function. 12960142 2003
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 GeneticVariation disease BEFREE Sections from formalin-fixed paraffin-embedded tumor blocks from 52 neuroblastoma cases (17 with localized, 35 with advanced disease) were subjected to immunohistochemistry for P-gp and GST-pi expressions. 12078865 2002
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE Meningioma cells frequently co-expressed P-gp and MRP1, while, most of the neuroblastoma cell lines express higher P-gp but lower MRP1 levels as compared to the other tumor types. 12125964 2002
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE To rule out the possibility that multidrug resistance (MDR) genes are involved in development of acquired drug resistance in murine neuroblastoma (rMNB/MDL) cells made resistant to MDL, the expression of Mdr1a, Mdr1b, Mdr2 (multidrug resistance/P-glycoprotein), and Mrp-1 (multidrug resistance associated protein) was examined in rMNB-MDL cells. 11172599 2001
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. 11474132 2001
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE The results show that BS-RNase selectively kills NB cells by inducing apoptosis and that this agent is active against mdr-1 expressing cells both in vitro and in vivo. 10536185 1999
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE Though Pgp expression is detectable and functional in neuroblastoma cells, but its presence does not provide much information to the complex phenomenon of chemotherapy resistance in patients. 9818076 1998
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE These findings suggest a clinical role for the MDR1 gene in specific subgroups of primary neuroblastoma. 9516848 1997
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Before chemotherapy, only 10% of the NB samples showed positivity for P-gp. 9317175 1997
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease CTD_human Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. 8761367 1996
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 Biomarker disease BEFREE Lovastatin, a nonreversible inhibitor of HMG-CoA reductase, induced extensive cytotoxicity that was restricted to drug-resistant P-glycoprotein-expressing neuroblastoma cell lines. 8612233 1996
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE A similar strong association has been observed between the expression of P-glycoprotein and outcome of treatment in certain malignancies in children, such as neuroblastoma, rhabdomyosarcoma, and acute lymphoblastic leukemia. 7642465 1995
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.400 AlteredExpression disease BEFREE Expression of mdr1/P-glycoprotein and p110 in neuroblastoma. 7891222 1995